Seborrhea-Pipeline Review, H2 2015

Seborrhea-Pipeline Review, H2 2015

  • Products Id :- GMDHC7274IDB
  • |
  • Pages: 34
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Seborrhea-Pipeline Review, H2 2015


Global Markets Direct's, 'Seborrhea-Pipeline Review, H2 2015', provides an overview of the Seborrhea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Seborrhea

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Seborrhea and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Seborrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Seborrhea pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Seborrhea

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Seborrhea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Seborrhea Overview 6

Therapeutics Development 7

Pipeline Products for Seborrhea-Overview 7

Pipeline Products for Seborrhea-Comparative Analysis 8

Seborrhea-Therapeutics under Development by Companies 9

Seborrhea-Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Seborrhea-Products under Development by Companies 12

Seborrhea-Companies Involved in Therapeutics Development 13

Biomar Microbial Technologies 13

EpiPharm AG 14

Maruho Co., Ltd. 15

Phosphagenics Limited 16

Seborrhea-Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 21

Drug Profiles 22

EPI-SK14-Drug Profile 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

hydrogen peroxide-Drug Profile 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

IB-07A081-Drug Profile 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

IB-07A085-Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

ketoconazole-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

lanoconazole-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Seborrhea-Recent Pipeline Updates 28

Seborrhea-Dormant Projects 29

Seborrhea-Discontinued Products 30

Seborrhea-Product Development Milestones 31

Featured News & Press Releases 31

Mar 17, 2015: Aclaris Therapeutics' Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor 31

Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor 31

Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

Number of Products under Development for Seborrhea, H2 2015 7

Number of Products under Development for Seborrhea-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Comparative Analysis by Early Stage Development, H2 2015 11

Products under Development by Companies, H2 2015 12

Seborrhea-Pipeline by Biomar Microbial Technologies, H2 2015 13

Seborrhea-Pipeline by EpiPharm AG, H2 2015 14

Seborrhea-Pipeline by Maruho Co., Ltd., H2 2015 15

Seborrhea-Pipeline by Phosphagenics Limited, H2 2015 16

Assessment by Monotherapy Products, H2 2015 17

Number of Products by Stage and Target, H2 2015 18

Number of Products by Stage and Mechanism of Action, H2 2015 19

Number of Products by Stage and Route of Administration, H2 2015 20

Number of Products by Stage and Molecule Type, H2 2015 21

Seborrhea Therapeutics-Recent Pipeline Updates, H2 2015 28

Seborrhea-Dormant Projects, H2 2015 29

Seborrhea-Discontinued Products, H2 2015 30

List of Figures

Number of Products under Development for Seborrhea, H2 2015 7

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Assessment by Monotherapy Products, H2 2015 17

Number of Products by Stage and Top 10 Targets, H2 2015 18

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 19

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 20

Number of Products by Stage and Top 10 Molecule Types, H2 2015 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Biomar Microbial Technologies

EpiPharm AG

Maruho Co., Ltd.

Phosphagenics Limited

Seborrhea Therapeutic Products under Development, Key Players in Seborrhea Therapeutics, Seborrhea Pipeline Overview, Seborrhea Pipeline, Seborrhea Pipeline Assessment

select a license

Single User License
USD 2000 INR 143760
Site License
USD 4000 INR 287520
Corporate User License
USD 6000 INR 431280



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]